SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

Pasireotide (aspartate) (trifluoroacetate salt)

Item No. 24092



Formal Name:	cyclo[(2R)-2-phenylglycyl-D-tryptophyl-L-lysyl-O-(phenylmethyl)-L-tyrosyl-L-phenylalanyl-(4R)-4-[[[(2-aminoethyl)amino]carbonyl]oxy]-L-prolyl], L-aspartate (1:2), trifluoroacetate salt
Synonym:	SOM230
MF:	$C_{58}H_{66}N_{10}O_9 \bullet 2C_4H_7NO_4 \bullet XCF_3COOH$
FW:	1,313.4
Purity:	≥95%
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Pasireotide (aspartate) (trifluoroacetate salt) is supplied as a crystalline solid. A stock solution may be made by dissolving the pasireotide (aspartate) (trifluoroacetate salt) in the solvent of choice. Pasireotide (aspartate) (trifluoroacetate salt) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of pasireotide (aspartate) (trifluoroacetate salt) in these solvents is approximately 33 mg/ml.

Pasireotide (aspartate) (trifluoroacetate salt) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, pasireotide (aspartate) (trifluoroacetate salt) should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. Pasireotide (aspartate) (trifluoroacetate salt) has a solubility of approximately 0.25 mg/ml in a 1:3 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Pasireotide is a somatostatin receptor (SSTR) agonist that binds selectively to SST_1, SST_2, SST_3, and SST_5 over SST_4 (IC_{50}s = 9.3, 1, 1.5, 0.16, and >100 nM, respectively, for human recombinant receptors).[1] It dose-dependently inhibits growth hormone release stimulated by growth hormone-releasing hormone (GHRH) in primary rat anterior pituitary cells and inhibits adrenocorticotropic hormone (ACTH) secretion by some primary human corticotrope adenomas at a concentration of 10 nM.[1,2] Pasireotide (10 nM) also inhibits ACTH release from and proliferation of mouse AtT20 pituitary corticotrope cells *in vitro* and inhibits tumor growth of subcutaneously implanted AtT20 cells *in vivo* in nude mice when administered at a dose of 1.5 µg per day.[3] Pasireotide (0.03 mg/kg) decreases plasma ACTH concentrations and tumor size in dogs with ACTH-dependent Cushing's disease.[4] Formulations containing pasireotide have been used in the treatment of acromegaly and Cushing's disease.

References

1. Bruns, C., Lewis, I., Briner, U., *et al. Eur. J. Endocrinol.* **146(5)**, 707-716 (2002).
2. Hofland, L.J., van der Hoek, J., Feelders, R., *et al. Eur. J. Endocrinol.* **152(4)**, 645-654 (2005).
3. Murasawa, S., Kageyama, K., Sugiyama, A., *et al. Mol. Cell. Endocrinol.* **394(1-2)**, 37-46 (2014).
4. Castillo, V., Theodoropoulou, M., Stalla, J., *et al. Neuroendocrinology* **94(2)**, 124-136 (2011).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM